Incadronate Disodium | Cimadronate | YM-175 | CAS#138330-18-4 | Bone Resorption Inhibitor

MedKoo Cat#: 329108 | Name: Incadronate Disodium

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Incadronate, also known as Cimadronate and YM-175, is a bone resorption inhibitor. Incadronate disodium inhibits macrophage migration to site of inflammation in vivo and proliferation and causes apoptosis in cancer cells in vitro. Incadronate disodium is a bone density conservation, antitumor and anti-inflammatory agent.

Chemical Structure

Incadronate Disodium

CAS#138330-18-4 (sodium)

Theoretical Analysis

MedKoo Cat#: 329108

Name: Incadronate Disodium

CAS#: 138330-18-4 (sodium)

Chemical Formula: C8H17NNa2O6P2

Exact Mass: 0.0000

Molecular Weight: 331.15

Elemental Analysis: C, 29.02; H, 5.17; N, 4.23; Na, 13.88; O, 28.99; P, 18.71

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.

Bulk Inquiry

Related CAS #

138330-18-4 (sodium) 124351-85-5 (free acid)

Synonym

Incadronate Disodium; Cimadronate; YM-175; YM 175; YM175; Incadronic acid;

IUPAC/Chemical Name

sodium ((cycloheptylamino)methylene)bis(hydrogen phosphonate)

InChi Key

PCSJAAWOSGCAFV-UHFFFAOYSA-L

InChi Code

InChI=1S/C8H19NO6P2.2Na/c10-16(11,12)8(17(13,14)15)9-7-5-3-1-2-4-6-7;;/h7-9H,1-6H2,(H2,10,11,12)(H2,13,14,15);;/q;2*+1/p-2

SMILES Code

[O-]P(C(P(O)([O-])=O)NC1CCCCCC1)(O)=O.[Na+].[Na+]

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>2 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 331.15 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Okamoto T, Yamagishi S, Inagaki Y, Amano S, Takeuchi M, Kikuchi S, Ohno S, Yoshimura A. Incadronate disodium inhibits advanced glycation end products-induced angiogenesis in vitro. Biochem Biophys Res Commun. 2002 Sep 20;297(2):419-24. PubMed PMID: 12237136. 2: Komatsubara S, Mori S, Mashiba T, Ito M, Li J, Kaji Y, Akiyama T, Miyamoto K, Cao Y, Kawanishi J, Norimatsu H. Long-term treatment of incadronate disodium accumulates microdamage but improves the trabecular bone microarchitecture in dog vertebra. J Bone Miner Res. 2003 Mar;18(3):512-20. PubMed PMID: 12619936. 3: Li C, Mori S, Li J, Kaji Y, Akiyama T, Kawanishi J, Norimatsu H. Long-term effect of incadronate disodium (YM-175) on fracture healing of femoral shaft in growing rats. J Bone Miner Res. 2001 Mar;16(3):429-36. PubMed PMID: 11277259. 4: Ohno Y, Yamada Y, Usu T, Takahashi K, Tsuchiya F, Ohtani H, Sato H, Sawada Y, Iga T. Pharmacokinetic and pharmacodynamic analysis of the antihypercalcemic effect of incadronate disodium in rats. Biol Pharm Bull. 2001 Nov;24(11):1290-3. PubMed PMID: 11725966. 5: Akiyama T, Mori S, Mashiba T, Miyamoto K, Komatsubara S, Cao Y, Manabe T, Norimatsu H, Dobashi H, Tokuda M. Incadronate disodium inhibits joint destruction and periarticular bone loss only in the early phase of rat adjuvant-induced arthritis. J Bone Miner Metab. 2005;23(4):295-301. PubMed PMID: 15981025. 6: Li J, Mori S, Mashiba T, Kaji Y, Taki M, Komatsubara S, Kawanishi J, Norimatsu H. Preadministration of incadronate disodium can prevent bone loss in rat proximal tibial metaphysis when induced by hindlimb immobilization by bandage. Bone. 1998 Nov;23(5):459-63. PubMed PMID: 9823453. 7: Takano Y, Tanizawa T, Mashiba T, Endo N, Nishida S, Takahashi HE. Maintaining bone mass by bisphosphonate incadronate disodium (YM175) sequential treatment after discontinuation of intermittent human parathyroid hormone (1-34) administration in ovariectomized rats. J Bone Miner Res. 1996 Feb;11(2):169-77. PubMed PMID: 8822340. 8: Shigematsu M, Shomi S, Iwao H, Ochi H. New bone-seeking agent: animal study of Tc-99m-incadronate. Ann Nucl Med. 2002 Feb;16(1):55-9. PubMed PMID: 11922209. 9: Tani-Ishii N, Minamida G, Saitoh D, Chieda K, Omuro H, Sugaya A, Hamada N, Takahashi Y, Kiyohara S, Kashima I, Teranaka T, Umemotot T. Inhibitory effects of incadronate on the progression of rat experimental periodontitis by porphyromonas gingivalis infection. J Periodontol. 2003 May;74(5):603-9. PubMed PMID: 12816291. 10: Tamura Y, Miyakoshi N, Itoi E, Abe T, Kudo T, Tsuchida T, Kasukawa Y, Sato K. Long-term effects of withdrawal of bisphosphonate incadronate disodium (YM175) on bone mineral density, mass, structure, and turnover in the lumbar vertebrae of ovariectomized rats. J Bone Miner Res. 2001 Mar;16(3):541-9. PubMed PMID: 11277272. 11: Miyakoshi N, Sato K, Tamura Y, Tsuchida T, Kudo T, Kasukawa Y. Evaluation of long-term sequential changes in bone mass and strength following withdrawal of incadronate disodium (YM175) in ovariectomized rats. J Orthop Sci. 2001;6(2):167-76. PubMed PMID: 11484104. 12: Saito M, Mori S, Mashiba T, Komatsubara S, Marumo K. Collagen maturity, glycation induced-pentosidine, and mineralization are increased following 3-year treatment with incadronate in dogs. Osteoporos Int. 2008 Sep;19(9):1343-54. doi: 10.1007/s00198-008-0585-3. Epub 2008 Mar 29. PubMed PMID: 18373056. 13: Liu C, Cao YP, Yang X, Mashiba T, Mori S. [Long-term and high-dose bisphosphonate administration causes no bone over-mineralization]. Zhonghua Yi Xue Za Zhi. 2009 Nov 17;89(42):2968-71. Chinese. PubMed PMID: 20137705. 14: Ueda T, Suzuki H, Akakura K, Ishihara M, Kamiya N, Komiya A, Shimbo M, Suyama T, Sakamoto S, Ichikawa T. Bisphosphonate and low-dose dexamethasone treatment for patients with hormone-refractory prostate cancer. Hinyokika Kiyo. 2006 Jul;52(7):515-21. PubMed PMID: 16910582. 15: Tsunematsu R, Saito T, Iguchi H, Fukuda T, Tsukamoto N. Hypercalcemia due to parathyroid hormone-related protein produced by primary ovarian clear cell adenocarcinoma: case report. Gynecol Oncol. 2000 Feb;76(2):218-22. PubMed PMID: 10637074.